Profile picture

Doctor Jurgen Bogoviku

University hospital Jena, Jena (Germany)
Membership: ESC Professional Member HFA Member
Follow
Logo ESC

Contributor content

Dynamics in creatinine in patients with heart failure presenting with pulmonary embolism treated by ultrasound-assisted, catheter-directed thrombolysis versus mechanical thrombectomy: single center
Presentation
Dynamics in creatinine in patients with heart failure presenting with pulmonary embolism treated by ultrasound-assisted, catheter-directed thrombolysis versus mechanical thrombectomy: single center
Tapse/spap and rv/lv ratio in pulmonary embolism treated by ultrasound-assisted, catheter-directed thrombolysis versus mechanical thrombectomy: single center experience
Presentation
Tapse/spap and rv/lv ratio in pulmonary embolism treated by ultrasound-assisted, catheter-directed thrombolysis versus mechanical thrombectomy: single center experience
Renal function in patients with acute decompensated de novo heart failure treated with the SGLT2 inhibitor empagliflozin: a secondary analysis of the EMPAG-HF trial
Presentation
Renal function in patients with acute decompensated de novo heart failure treated with the SGLT2 inhibitor empagliflozin: a secondary analysis of the EMPAG-HF trial
Acute effect of empagliflozin on echocardiographic parameter in de novo heart failure: a secondary analysis of the EMPAG-HF trial
Presentation
Acute effect of empagliflozin on echocardiographic parameter in de novo heart failure: a secondary analysis of the EMPAG-HF trial
Acute diuretic effect of empagliflozin in de novo heart failure: a secondary analysis of the EMPAG-HF trial
Presentation
Acute diuretic effect of empagliflozin in de novo heart failure: a secondary analysis of the EMPAG-HF trial
Acute diuretic response of empagliflozin according to LVEF:A secondary analysis of the EMPAG-HF trial
Presentation
Acute diuretic response of empagliflozin according to LVEF:A secondary analysis of the EMPAG-HF trial
Metabolic impact of empagliflozin in patients with acute decompensated heart failure:A secondary analysis of the EMPAG-HF trial
Presentation
Metabolic impact of empagliflozin in patients with acute decompensated heart failure:A secondary analysis of the EMPAG-HF trial
Kidney parameters of the EMPAGHF cohort.
Presentation
Kidney parameters of the EMPAGHF cohort.
Acute effect of empagliflozin on serum uric acid - a subanalysis of the EMPAG-HF trial (effects of empagliflozin on diuresis and renal function in patients with acute decompensated heart failure)
Presentation
Acute effect of empagliflozin on serum uric acid - a subanalysis of the EMPAG-HF trial (effects of empagliflozin on diuresis and renal function in patients with acute decompensated heart failure)
Prospective evaluation of left heart echocardiographic parameters of the EMPAG-HF patient cohort(effects of empagliflozin on diuresis and renal function in patients with acute decompensated HF)
Presentation
Prospective evaluation of left heart echocardiographic parameters of the EMPAG-HF patient cohort(effects of empagliflozin on diuresis and renal function in patients with acute decompensated HF)

ESC 365 is supported by